Immunotherapy successful against deadly breast cancer

October 23, 2018

Triple-negative breast cancer is so called since its cells lack receptors for two hormones (estrogen and progesterone) and one protein (HER2).

While this cancer is uncommon, it is one of the most aggressive and deadly.

In the majority of cases, it quickly becomes resistant to chemotherapy and continues to spread through the body.

According to existing research, triple-negative breast cancer makes up about 10–15 percent of diagnosed breast cancers. This form of cancer is also more likely to affect younger women in their 40s or 50s.

Read More on Medical News Today